People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. | — | Biotechnology | Series D+ | $294.0M | $2.2B | 2020 |
| ArcherDX, Inc. | — | Other Health Care | Series C | $115.1M | $35.6M | 2020 |
| Verrica Pharmaceuticals Inc. | — | Pharmaceuticals | Series C | $77.5M | $269.0M | 2025 |
| Xalud Therapeutics, Inc. | — | Biotechnology | Series B | $30.5M | $495.1M | 2020 |
| Liquidia Corp | — | Biotechnology | Series B | $21.7M | $616.9M | 2021 |
| Dova Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2016 |
Paul B. Manning at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul B. Manning on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Manning | 2 | 6 |
| Sean Stalfort | 2 | 5 |
| James C. Reebals | 2 | 2 |
| Jayson Rieger | 2 | 2 |
| Diem B. Nguyen | 2 | 2 |
| Stephen Bloch | 1 | 15 |
| Kyle Lefkoff | 1 | 9 |
| David B. Johnson | 1 | 6 |
| Stephen Collins | 1 | 5 |
| PHILLIP B. DONENBERG | 1 | 4 |
| Jason Myers | 1 | 4 |
| Sean Nolan | 1 | 3 |
| Noah Rosenberg | 1 | 3 |
| Marvin H Caruthers | 1 | 2 |
| Marvin Caruthers | 1 | 2 |
| Matthew Davidson | 1 | 2 |
| Steven J. Kafka | 1 | 2 |
| Michael Kaseta | 1 | 2 |
| John Kirby | 1 | 2 |
| Todd Druley | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.